Building on the Industrial Revolution, the modern sedentary age coupled with abundant cheap food has greatly exacerbated the obesity problem. According to CDC data, 1 in 5 adults in the US and territories could be classified as obese. Even worse, 22 states had obesity rates above 35% in 2022.
For shareholders, this looming narrative had a suppressive effect on PFE stock as the vaccine demand died out. From the all-time high of $55 in December 2021, PFE shares have had a 52-week average of $29.96, aligning with the present price of $28.66 per share. Danuglipron belongs to the family of GLP-1 agonists, which are now prevalent in the treatment of obesity-related issues, of which diabetes is the main driver. Optimization studies will take place in the second half of 2024 to determine dosing.
Improving on obesity and diabetes treatments, the company now counts on Mounjaro, Zepbound and Jardiance for revenue growth. In Q1 earnings, these drugs were mainly responsible for the quarter’s 26% sales boost of $8.76 billion, delivering a $2.2 billion net income. Although China also approved Novo Nordisk’s Ozempic in 2021 and Wegovy in late June, Novo Nordisk is likely to face a wind down as the patent on semaglutide expires in 2026. At that point, we are likely to see a flood of Chinese generic obesity drugs, a similar pattern that happened with the
United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »
Source: Investingcom - 🏆 450. / 53 Read more »